AstraZeneca (NYSE: AZN) announced yesterday that the US Food and Drug Administration (FDA) has approved BRILINTA™ (ticagrelor) tablets to reduce the rate of heart attack (myocardial infarction [MI]) and cardiovascular (CV) death in adult patients with acute coronary syndrome (ACS), compared to clopidogrel.
BRILINTA, a new oral antiplatelet medicine, is indicated to reduce the rate of thrombotic cardiovascular events in patients with ACS (unstable angina [UA] non-ST-elevation myocardial infarction [NSTEMI], or ST-elevation myocardial infarction [STEMI]). BRILINTA has been shown to reduce the rate of a combined endpoint of CV death, MI or stroke compared to clopidogrel. The difference between treatments was driven by CV death and MI with no difference in stroke. In patients treated with an artery-opening procedure known as percutaneous coronary intervention (PCI), BRILINTA reduces the rate of stent thrombosis. BRILINTA has been studied in ACS in combination with aspirin. Maintenance doses of aspirin above 100 mg decreased the effectiveness of BRILINTA. Avoid maintenance doses of aspirin above 100 mg daily.
- Fda Approves New Medicine Brilinta™ (monsterphotoiso.wordpress.com)
- FDA Approves AstraZeneca PLC Heart Drug Brilinta (biospace.com)
- AstraZeneca shares up 3.7% on Brilinta approval (marketwatch.com)
- FDA Approves Blood Thinner Brilinta for Heart Patients (nlm.nih.gov)
- FDA Approves New Medicine BRILINTA™ (Ticagrelor) for Use in the US (prnewswire.com)
- BREAKING NEWS: AstraZeneca wins FDA approval for blockbuster hopeful Brilinta (fiercebiotech.com)
- FDA Approves Anticlotting Brilinta from AstraZeneca to Compete with Plavix (ducknetweb.blogspot.com)
- FDA approves new AstraZeneca blood thinner (seattlepi.com)
- AstraZeneca Blood Thinner Wins FDA Approval to Rival Plavix (businessweek.com)
- FDA approves new AstraZeneca blood thinner (seattletimes.nwsource.com)